keyword
MENU ▼
Read by QxMD icon Read
search

HER2+ metastatic breast cancer

keyword
https://www.readbyqxmd.com/read/29333945/remarkable-response-with-pembrolizumab-plus-albumin-bound-paclitaxel-in-2-cases-of-her2-positive-metastatic-breast-cancer-who-have-failed-to-multi-anti-her2-targeted-therapy
#1
Bian Li, Wang Tao, Zhang Shao-Hua, Q U Ze-Rui, Jin Fu-Quan, L I Fan, Jiang Ze-Fei
In clinical practice, one subgroup patients of breast cancer might have developed resistance to multi-anti-HER2 targeted drugs(trastuzumab,lapatinib and/or T-DM1) and can not benefit from the anti-HER2 targeted therapy continuously. We attempt to change the next therapic way for these patients.Two patients with metastatic breast cancer who have failed to multi-anti-HER2 targeted therapy were treated with pembrolizumab(2mg/Kg, day1) plus albumin-bound paclitaxel(125mg/m2, day1,8) every 3 weeks.CT evaluation and HER2 ECD test were performed every 2 cycles...
January 15, 2018: Cancer Biology & Therapy
https://www.readbyqxmd.com/read/29332137/variation-in-guideline-concordant-care-for-elderly-patients-with-metastatic-breast-cancer-in-the-united-states
#2
Philip D Poorvu, Ines Vaz-Luis, Rachel A Freedman, Nancy U Lin, William T Barry, Eric P Winer, Michael J Hassett
PURPOSE: Prior studies have identified shortcomings in the quality of care for early-stage breast cancer. Guidelines recommend systemic therapy for metastatic breast cancer (MBC), but few studies have examined guideline concordance for these patients. METHODS: We used Surveillance, Epidemiology, and End Results (SEER)-Medicare data to identify patients aged ≥ 66 diagnosed in 2010-2011 with de novo MBC who were continuously enrolled in fee-for-service Medicare...
January 13, 2018: Breast Cancer Research and Treatment
https://www.readbyqxmd.com/read/29329006/ongoing-unmet-needs-in-treating-estrogen-receptor-positive-her2-negative-metastatic-breast-cancer
#3
REVIEW
Gül A Başaran, Chris Twelves, Véronique Diéras, Javier Cortés, Ahmad Awada
Estrogen receptor-positive (ER+)/human epidermal growth factor receptor 2 negative (HER2-) advanced or metastatic breast cancer (MBC) is the most common MBC subtype and currently remains incurable, with a median overall survival of 24.8 months (95% confidence interval, 21.3-30.3). Common sites of metastases are bone, viscera, and brain, causing significant symptoms that negatively affect patient functioning, quality of life (QoL), and work productivity. Guidelines state that endocrine therapy (ET) is preferable to chemotherapy as first-line treatment for patients with ER+ MBC, regardless of limited visceral metastases, unless rapid tumor response is required or ET resistance is suspected...
December 6, 2017: Cancer Treatment Reviews
https://www.readbyqxmd.com/read/29326401/efficacy-and-tolerability-of-trastuzumab-emtansine-in-advanced-human-epidermal-growth-factor-receptor-2-positive-breast-cancer
#4
W Yeo, M Y Luk, I S Soong, T Ys Yuen, T Y Ng, F Kf Mo, K Chan, S Y Wong, J Tsang, C Leung, J Js Suen, R Kc Ngan
INTRODUCTION: The management of human epidermal growth factor receptor 2 (HER2)-positive breast cancer has changed dramatically with the introduction and widespread use of HER2-targeted therapies. There is, however, relatively limited real-world information about the effectiveness and safety of trastuzumab emtansine (T-DM1) in the Hong Kong Chinese patients. We assessed the efficacy and toxicity profiles among local patients with HER2-positive advanced breast cancer who had received T-DM1 therapy in the second-line setting and beyond...
January 12, 2018: Hong Kong Medical Journal, Xianggang Yi Xue za Zhi
https://www.readbyqxmd.com/read/29321587/distribution-analysis-of-epertinib-in-brain-metastasis-of-her2-positive-breast-cancer-by-imaging-mass-spectrometry-and-prospect-for-antitumor-activity
#5
Yukari Tanaka, Michinari Hirata, Satomi Shinonome, Mikinori Torii, Ken-Ichi Nezasa, Hidekazu Tanaka
Epertinib (S-222611) is a potent, reversible, and selective tyrosine kinase inhibitor of epidermal growth factor receptor (EGFR), human EGFR2 (HER2), and human EGFR4. We developed experimental brain metastasis models by intraventricular injection (intraventricular injection mouse model; IVM) of HER2-positive breast cancer (MDA-MB-361-luc-BR2/BR3) or T790M-EGFR-positive lung cancer (NCI-H1975-luc) cells. After a single oral administration, epertinib and lapatinib concentrations in brain metastatic regions were analyzed by quantitative imaging mass spectrometry...
January 10, 2018: Scientific Reports
https://www.readbyqxmd.com/read/29315431/receptor-conversion-in-distant-breast-cancer-metastases-a-systematic-review-and-meta-analysis
#6
Willemijne A M E Schrijver, Karijn P M Suijkerbuijk, Carla H van Gils, Elsken van der Wall, Cathy B Moelans, Paul J van Diest
Background: In metastatic breast cancer, hormone and/or human epidermal growth factor receptor 2 (HER2)-targeted therapy decision-making is still largely based on tissue characteristics of the primary tumor. However, a change of estrogen receptor alpha (ERα), progesterone receptor (PR), and HER2 status in distant metastases has frequently been reported. The actual incidence of this phenomenon has been debated. Methods: We performed a meta-analysis including 39 studies assessing receptor conversion from primary breast tumors to paired distant breast cancer metastases...
January 5, 2018: Journal of the National Cancer Institute
https://www.readbyqxmd.com/read/29315394/a-phase-i-ii-study-of-the-combination-of-lapatinib-and-oral-vinorelbine-in-her2-positive-metastatic-breast-cancer
#7
Tom Wei-Wu Chen, Dah-Cherng Yeh, Tsu-Yi Chao, Ching-Hung Lin, Louis Wing-Cheong Chow, Dwan-Ying Chang, Yao-Yu Hsieh, Shu-Min Huang, Ann-Lii Cheng, Yen-Shen Lu, Taiwan Breast Cancer Consortium
Background: The combination of lapatinib and oral vinorelbine for HER2 positive metastatic breast cancer (MBC) is convenient but with uncertain toxicity profiles. A Phase I/II study was designed to understand the tolerability and efficacy of this combination treatment. Method: Female MBC patients with HER2 positive were eligible. Lapatinib was given once daily and oral vinorelbine was given on Days 1 and 8 of a 21-day cycle. A 3 + 3 standard dose-escalation rule was applied in the Phase I study...
January 5, 2018: Japanese Journal of Clinical Oncology
https://www.readbyqxmd.com/read/29311117/expanded-genomic-profiling-of-circulating-tumor-cells-in-metastatic-breast-cancer-patients-to-assess-biomarker-status-and-biology-over-time
#8
Mark Jesus M Magbanua, Hope S Rugo, Denise M Wolfe, Louai Hauranieh, Ritu Roy, Praveen Pendyala, Eduardo Sosa, Janet H Scott, Jin Sun Lee, Brandelyn N Pitcher, Terry M Hyslop, William T Barry, Steven J Isakoff, Maura N Dickler, Laura J Van't Veer, John W Park
Purpose: We profiled circulating tumor cells (CTCs) patients to study the biology of blood-borne metastasis and to monitor biomarker status in metastatic breast cancer (MBC).Methods: CTCs were isolated from 105 MBC patients using EPCAM-based immunomagnetic enrichment and fluorescence-activated cells sorting (IE/FACs), 28 of whom had serial CTC analysis (74 samples, 2-5 time points). CTCs were subjected to microfluidic-based multiplex QPCR array of 64 cancer-related genes (n=151) and genome-wide copy number analysis by array comparative genomic hybridization (n=49)...
January 8, 2018: Clinical Cancer Research: An Official Journal of the American Association for Cancer Research
https://www.readbyqxmd.com/read/29309924/aggressive-triple-negative-breast-cancers-have-unique-molecular-signature-on-the-basis-of-mitochondrial-genetic-and-functional-defects
#9
Manti Guha, Satish Srinivasan, Pichai Raman, Yuefu Jiang, Brett A Kaufman, Deanne Taylor, Dawei Dong, Rumela Chakrabarti, Martin Picard, Russ P Carstens, Yuko Kijima, Mike Feldman, Narayan G Avadhani
Metastatic breast cancer is a leading cause of cancer-related deaths in women worldwide. Patients with Triple Negative breast cancer (TNBCs), a highly aggressive tumor subtype, have a particularly poor prognosis. Multiple reports demonstrate that altered content of the multicopy mitochondrial genome (mtDNA) in primary breast tumors correlates with poor prognosis. We earlier reported that mtDNA copy number reduction in breast cancer cell lines induces an epithelial-mesenchymal transition associated with metastasis...
January 5, 2018: Biochimica et Biophysica Acta
https://www.readbyqxmd.com/read/29303361/outcomes-research-examining-treatments-quality-of-life-and-costs-in-her2-negative-and-triple-negative-metastatic-breast-cancer-a-systematic-literature-review
#10
Monika Parisi, Corey Pelletier, Dasha Cherepanov, Michael S Broder
AIM: With the aggregation of real-world data in healthcare, opportunities for outcomes research are growing. In this study, we summarize published literature examining comparative effectiveness research (CER), treatment patterns, quality of life (QoL) and costs in HER2-negative and triple-negative (TN) metastatic breast cancer (mBC). METHODS: PubMed (2010-January 2016) and four conferences (2013-January 2016) were searched using MeSH/keywords, including mBC, QoL, morbidity and therapeutics...
January 5, 2018: Journal of Comparative Effectiveness Research
https://www.readbyqxmd.com/read/29302858/subgroup-analysis-of-patients-with-her2-negative-metastatic-breast-cancer-in-the-second-line-setting-from-a-phase-3-open-label-randomized-study-of-eribulin-mesilate-versus-capecitabine
#11
Xavier Pivot, Seock Ah Im, Matthew Guo, Frederik Marmé
This post hoc subgroup analysis of a large phase 3 study compared the efficacy and safety of eribulin versus capecitabine in patients with human epidermal growth factor receptor 2 (HER2)-negative metastatic breast cancer who received second-line treatment. In the phase 3 study, women with advanced/metastatic breast cancer and ≤ 3 prior chemotherapies were randomized 1:1 to eribulin mesilate 1.4 mg/m2 intravenously on days 1 and 8, or twice-daily oral capecitabine 1.25 g/m2 on days 1-14 (21-day cycles)...
January 4, 2018: Breast Cancer: the Journal of the Japanese Breast Cancer Society
https://www.readbyqxmd.com/read/29295986/macrophages-orchestrate-breast-cancer-early-dissemination-and-metastasis
#12
Nina Linde, Maria Casanova-Acebes, Maria Soledad Sosa, Arthur Mortha, Adeeb Rahman, Eduardo Farias, Kathryn Harper, Ethan Tardio, Ivan Reyes Torres, Joan Jones, John Condeelis, Miriam Merad, Julio A Aguirre-Ghiso
Cancer cell dissemination during very early stages of breast cancer proceeds through poorly understood mechanisms. Here we show, in a mouse model of HER2+ breast cancer, that a previously described sub-population of early-evolved cancer cells requires macrophages for early dissemination. Depletion of macrophages specifically during pre-malignant stages reduces early dissemination and also results in reduced metastatic burden at end stages of cancer progression. Mechanistically, we show that, in pre-malignant lesions, CCL2 produced by cancer cells and myeloid cells attracts CD206+/Tie2+ macrophages and induces Wnt-1 upregulation that in turn downregulates E-cadherin junctions in the HER2+ early cancer cells...
January 2, 2018: Nature Communications
https://www.readbyqxmd.com/read/29288366/de-novo-metastasis-in-breast-cancer-occurrence-and-overall-survival-stratified-by-molecular-subtype
#13
David J Press, Megan E Miller, Erik Liederbach, Katherine Yao, Dezheng Huo
Breast cancer molecular subtypes, categorized jointly by hormone receptors (HR) and human epidermal growth factor-2 (HER2), are utilized to guide systemic therapy. We hypothesized distinct patterns of de novo metastasis and overall survival by molecular subtype using a retrospective cohort of 399,772 women in the National Cancer Database diagnosed with first primary invasive breast cancer between 2010 and 2014, of whom 13,924 were diagnosed with de novo metastasis from 2010 to 2013 and had follow up data. The relationship of molecular subtype with patient and tumor characteristics, including site of de novo metastasis, were examined using Chi-squared tests...
December 29, 2017: Clinical & Experimental Metastasis
https://www.readbyqxmd.com/read/29287189/human-epidermal-growth-factor-receptor-2-dual-blockade-with-trastuzumab-and-pertuzumab-in-real-life-italian-clinical-practice-versus-the-cleopatra-trial-results
#14
Sabino De Placido, Mario Giuliano, Francesco Schettini, Claudia Von Arx, Giuseppe Buono, Ferdinando Riccardi, Daniela Cianniello, Roberta Caputo, Fabio Puglisi, Marta Bonotto, Alessandra Fabi, Domenico Bilancia, Mariangela Ciccarese, Vito Lorusso, Andrea Michelotti, Dario Bruzzese, Bianca Maria Veneziani, Mariavittoria Locci, Michelino De Laurentiis, Grazia Arpino
OBJECTIVES: Given their inclusion and exclusion criteria, randomized clinical trials (RCT) might not include a population that truly mirrors real life (RL). This raises concerns about the applicability of RCT results in clinical practice. We evaluated the efficacy of anti-HER2 treatment with pertuzumab combined with trastuzumab and a taxane as first-line treatment for HER2-positive metastatic breast cancer in a RL setting, and compared the safety results obtained in our population versus the experimental cohort of the CLEOPATRA RCT, which led to the approval of this therapy...
December 26, 2017: Breast: Official Journal of the European Society of Mastology
https://www.readbyqxmd.com/read/29285378/phase-ii-study-of-neoadjuvant-anthracycline-combined-with-nanoparticle-albumin-bound-paclitaxel-for-human-epidermal-growth-factor-receptor-2-negative-breast-cancer
#15
Emi Ishigami, Masahiro Sakakibara, Junta Sakakibara, Toshiaki Iwase, Shoko Hayama, Takahito Masuda, Ayako Nakagawa, Takeshi Nagashima, Takafumi Sangai, Hiroshi Fujimoto, Masayuki Otsuka
Neoadjuvant chemotherapy (NAC) with anthracyclines followed by taxane chemotherapy has become the standard treatment for patients with locally advanced, operable breast cancer. Recently, the efficacy of nanoparticle albumin-bound paclitaxel (nab-PTX) for metastatic breast cancer was reported. However, there are still few studies of a neoadjuvant regimen including nab-PTX. Thus, the present phase II study evaluated the efficacy and safety of 5-fluorouracil, epirubicin and cyclophosphamide (FEC regimen) followed by nab-PTX as neoadjuvant treatment for operable human epidermal growth factor receptor 2 (HER2)-negative breast cancer...
December 2017: Molecular and Clinical Oncology
https://www.readbyqxmd.com/read/29284708/esr1-methylation-a-liquid-biopsy-based-epigenetic-assay-for-the-follow-up-of-patients-with-metastatic-breast-cancer-receiving-endocrine-treatment
#16
Sofia Mastoraki, Areti Strati, Eleni Tzanikou, Maria Chimonidou, Helen Politaki, Alexandra Voutsina, Amanda Psyrri, Vasilis Georgoulias, Evi S Lianidou
PURPOSE: Liquid biopsy provides real-time monitoring of tumor evolution and response to therapy through analysis of CTCs and plasma-ctDNA. ESR1 epigenetic silencing potentially affects response to endocrine treatment. We evaluated ESR1 methylation in CTCs and paired plasma-ctDNA. We evaluated ESR1 methylation in CTCs and paired plasma-ctDNA as a potential biomarker for response to everolimus/exemestane treatment. EXPERIMENTAL DESIGN: A highly sensitive and specific real-time MSP assay for ESR1 methylation was developed and validated in: a) 65 primary breast tumors (FFPEs), b) EpCAM+ CTC-fractions (122 patients and 30 healthy donors; HD), c) plasma-ctDNA (108 patients and 30HD), d) in CTCs (CellSearch®) and in paired plasma-ctDNA for 58 BrCa patients...
December 28, 2017: Clinical Cancer Research: An Official Journal of the American Association for Cancer Research
https://www.readbyqxmd.com/read/29284349/association-of-hypertension-and-treatment-outcomes-in-advanced-stage-non-small-cell-lung-cancer-patients-treated-with-bevacizumab-or-non-bevacizumab-containing-regimens
#17
Lily Z Yan, Emily V Dressler, Val R Adams
Background Studies suggest that bevacizumab-induced hypertension is prognostic of better outcomes in bevacizumab-treated patients with metastatic colorectal, HER2-negative breast, kidney, and pancreatic cancer. Few have examined this correlation in metastatic non-small cell lung cancer and evaluated whether hypertension independent of bevacizumab can improve the treatment outcomes. Objectives The primary objective was to determine the effect of hypertension on the overall response of advanced non-small cell lung cancer patients from start of the first-line chemotherapy to maintenance therapy...
January 1, 2017: Journal of Oncology Pharmacy Practice
https://www.readbyqxmd.com/read/29282695/strategies-and-progress-of-endocrine-therapy-for-patients-with-metastatic-breast-cancer
#18
Hope S Rugo, Huiping Li, Xinyu Gui
Breast cancer is one of the most prevalent cancers and the leading causes of cancer mortality in women worldwide and in China. For hormone receptor-positive (HR+) breast cancer, accounting for approximately 60-80% of breast cancer, endocrine therapy (ET) is the primary treatment strategy. For patients with HR+ metastatic breast cancer (MBC), there are many endocrine-based treatment options that can improve long-term outcomes and optimize quality of life. With the emergence and availability of new and effective agents, the options for ET have expanded in the last two decades...
2017: Advances in Experimental Medicine and Biology
https://www.readbyqxmd.com/read/29281678/the-natural-compound-jatrophone-interferes-with-wnt-%C3%AE-catenin-signaling-and-inhibits-proliferation-and-emt-in-human-triple-negative-breast-cancer
#19
Iram Fatima, Ikbale El-Ayachi, Ling Taotao, M Angeles Lillo, Raya Krutilina, Tiffany N Seagroves, Tomasz W Radaszkiewicz, Miroslav Hutnan, Vitezslav Bryja, Susan A Krum, Fatima Rivas, Gustavo A Miranda-Carboni
Metastatic breast cancer is the leading cause of worldwide cancer-related deaths among women. Triple negative breast cancers (TNBC) are highly metastatic and are devoid of estrogen receptor (ER), progesterone receptor (PR) and human epidermal growth factor receptor 2 (HER2) amplification. TNBCs are unresponsive to Herceptin and/or anti-estrogen therapies and too often become highly chemoresistant when exposed to standard chemotherapy. TNBCs frequently metastasize to the lung and brain. We have previously shown that TNBCs are active for oncogenic Wnt10b/β-catenin signaling and that WNT10B ligand and its downstream target HMGA2 are predictive of poorer outcomes and are strongly associated with chemoresistant TNBC metastatic disease...
2017: PloS One
https://www.readbyqxmd.com/read/29277798/safety-and-efficacy-of-low-dose-nanoparticle-albumin-bound-paclitaxel-for-her2-negative-metastatic-breast-cancer
#20
Tsutomu Takashima, Hidemi Kawajiri, Takeo Nishimori, Seika Tei, Shigehiko Nishimura, Shigehito Yamagata, Shinya Tokunaga, Yoko Mizuyama, Takeshi Sunami, Kenji Tezuka, Katsumi Ikeda, Yoshinari Ogawa, Shinichiro Kashiwagi, Satoru Noda, Naoyoshi Onoda, Tetsuro Ishikawa, Shinzoh Kudoh, Minoru Takada, Kosei Hirakawa, Masaichi Ohira
BACKGROUND/AIM: Nab-paclitaxel (nab-PTX) is an albumin-bound paclitaxel formulation. Although nab-PTX has shown superior efficacy compared to conventional paclitaxel (PTX) in metastatic breast cancer (MBC), chemotherapy-induced peripheral neuropathy (CIPN) was more frequently observed in nab-PTX. In this study, we aimed to estimate the feasibility of the nab-PTX 175 mg/m2/3weeks regimen. PATIENTS AND METHODS: Patients having metastatic or inoperable HER2-negative breast cancer received 175 mg/m2 of nab-PTX every three weeks...
January 2018: Anticancer Research
keyword
keyword
22191
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"